The latest from BioStock
» BrainCool's US collaboration with ZOLL officially launched – may be expanded
» Aptahem comments on the paused phase I study
» Stayble Therapeutics Phase IIb Study Nears Finish Line
» SynAct Pharma's CEO comments on the latest progress
» BrainCool received patent approval in the EU
Morning news
announces completion of enrollment in the Phase II study FOCUS w/ UV1 in patients with head and neck cancer. Read more.
Aino Health has decided on a rights issue of approximately SEK 12,7 million. Read more.
Bavarian Nordic receives a $120 million order from the US government for the company's smallpox and monkeypox vaccines. Read more.
Faron Pharmaceuticals will participate in the Canaccord Genuity 43rd Annual Growth Conference. Read more.
Reports
Annexin Pharmaceuticals Moberg Pharma
Invitation to presentation
Oncopeptides Optomed (amendment) Photocure
News since Wednesday lunch
Peptonic has published merger documents in connection with the merger with Pharmiva. Read more.
OncoZenge has announced that the company is pausing development of BupiZenge. Read more.
Cline Scientific has announced the outcome of the rights issue. Read more.
Realheart has announced the last day for trading in BTU and the first day for trading in series TO2 warrants. Read more.
Theresa Agnew has been appointed as the new CEO of BioGaia. Read more.
Mette-Marie Harild has resigned from his position in Qlifes board. Read more.
Emma Stromfelt has resigned as a board member of Coala-Life Group. Read more.
A study at University of Gothenburg gives hope for future treatment with anti-inflammatory intestinal bacteria in type 2 diabetes. Read more.
This morning's price development
Winner: Miris Holding 16,2%, Ectin Research 14,9%, Redwood Pharma 13,3%, Ziccum 8,4%, Spermosens 8,2%
Förlorare: OncoZenge -28,8%, Cline Scientific -20,3%, Odinwell -19,2%, Aino Health -15,7%, Annexin Pharmaceuticals -11,8%
Index: OMSX30 2200 -1,0%, Healthcare -1,15%
More from BioStock
» EU patent gives Scandion extended commercial exclusivity
» Saniona's CEO comments on the collaboration with AstronauTx
» Alligator Biosciences CSO presents CD40 portfolio at conference
» New study plan approved for WntResearch's Phase II study
» Lipum aims to complete Phase I study faster